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Introduction: Carbamazepine is associated with a significant risk of hypersensitivity reactions, 
including severe toxidermia such as Stevens-Johnson syndrome (SJ), toxic epidermal necrolysis 
(TEN) or drug rash with eosinophilia and systemic symptoms (DRESS). Predisposition to such 
reactions has recently been linked to the HLA-A*3101 allele in caucasian populations and the Swiss 
Agency for Therapeutic Products (Swissmedic) now recommends genotyping for this allele before 
starting carbamazepine. The aim of this review was to critically analyze the data that support this 
recommendation for preventing severe toxidermia.  
Method: Data from literature were reviewed to assess HLA-A*3101 prevalence in European 
populations, frequency of severe toxidermia associated with carbamazepine, sensitivity and specificity 
of HLA-A*3101 testing for predicting these toxidermia. The number needed to screen for preventing 
one severe reaction was calculated on the basis of these data and screening costs were estimated 
accordingly.  
Results: The prevalence of HLA-A*3101 is 2 to 5% in Northern Europe. The estimated incidence of 
carbamazepine-induced SJ/TEN and DRESS is at most 6 cases in 10´000. The sensitivity and 
specificity of the HLA-A*3101 allele for these severe toxidermia is 38% and 96%, respectively. Thus 
the number needed to screen for preventing one serious reaction is 4333 subjects. The screening 
costs for preventing one reaction are estimated at about 585'000 Swiss francs (considering the current 
test price of 135 Swiss francs).  
Conclusion: According to currently available data, routine HLA-A*3101 screening before starting 
carbamazepine is of disputable cost-effectiveness for preventing severe hypersensitivity reactions 
such as SJ, TEN or DRESS.  
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Objectives: Oxycodone is an agonist of µ-opioid receptors. Cytochromes P450 (CYP) 3A and 2D6 
are reported to be the main isoenzymes involved in its metabolism. Development of a physiologically-
based pharmacokinetic (PBPK) model is an approach to predict in vivo pharmacokinetic (PK) profile of 
oxycodone and its metabolites in different drug-drug interaction (DDI) scenarios.  
Method: A PBPK model was developed for oxycodone and its two primary metabolites, oxymorphone 
and noroxycodone, based on published in vitro and in vivo data using the Simcyp Population-based 
Simulator. Models were refined by top-down approach using a published clinical trial by Samer et al. 
(2010) where PK profiles of oxycodone and its 3 metabolites were monitored in 4 DDI scenarios: 
oxycodone administered alone or co-administered with CYP3A inhibitor ketoconazole and/or CYP2D6 
inhibitor quinidine. The fraction of the dose metabolized by every isoenzyme was modified in order to 
match the DDI prediction reported in the reference study. Ultimately, the reliability of the model was 
tested against seven published DDI scenarios. The impact of CYP3A and CYP2D6 inhibition by 
